DZD-8586 is under clinical development by Dizal Pharmaceutical and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase II drugs for Diffuse Large B-Cell Lymphoma have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DZD-8586’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DZD-8586 is under development for the treatment of non-hodgkin lymphoma, b-cell non-Hodgkin lymphoma, relapsed and refractory chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma, CNS Lymphoma, follicular lymphoma, marginal zone B-cell lymphoma. It is administered through oral route. It acts by targeting Bruton’s tyrosine kinase (BTK).
Dizal Pharmaceutical overview
Dizal Pharmaceutical (Dizal) is a biopharmaceutical company. It focuses on research, development, and commercialization of therapies to treat cancer and immunological diseases. The company’s lead product candidate ZEGFROVY, which is at marketing approval stage for treatment of solid tumors. Its product pipeline includes other drug programs such as JAUKPO to treat hematological malignancy, solid tumors, and immunological diseases; DZD8586 for treatment of hematological malignancy; and DZD2269 and DZD1516 to treat solid tumors. The company operates with additional facilities in Beijing, Wuxi, Chengdu, China. Dizal is headquartered in Shanghai, China.
For a complete picture of DZD-8586’s drug-specific PTSR and LoA scores, buy the report here.